Zai Lab (ZLAB) Upgraded by BidaskClub to “Sell”

Zai Lab (NASDAQ:ZLAB) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Wednesday, January 10th.

ZLAB has been the subject of a number of other reports. Leerink Swann initiated coverage on shares of Zai Lab in a report on Monday, October 16th. They set an “outperform” rating and a $42.00 price target for the company. Citigroup initiated coverage on shares of Zai Lab in a research report on Monday, October 16th. They set a “buy” rating on the stock. Finally, JPMorgan Chase & Co. assumed coverage on shares of Zai Lab in a research report on Monday, October 16th. They set a “neutral” rating and a $32.00 price objective on the stock.

Shares of Zai Lab (ZLAB) opened at $25.35 on Wednesday. Zai Lab has a 1-year low of $20.67 and a 1-year high of $35.74.

Large investors have recently added to or reduced their stakes in the company. FNY Partners Fund LP purchased a new stake in shares of Zai Lab in the 3rd quarter worth about $137,000. Pinebridge Investments L.P. purchased a new stake in shares of Zai Lab in the 3rd quarter worth about $945,000. Finally, Gilder Gagnon Howe & Co. LLC grew its position in Zai Lab by 64.9% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 917,123 shares of the company’s stock valued at $19,471,000 after purchasing an additional 360,801 shares during the last quarter. 18.14% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Zai Lab (ZLAB) Upgraded by BidaskClub to “Sell”” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/06/zai-lab-zlab-upgraded-at-bidaskclub.html.

Zai Lab Company Profile

Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases.

Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply